ESG Planning DBA Harper Investing Makes New $459,000 Investment in Danaher Co. (NYSE:DHR)

ESG Planning DBA Harper Investing purchased a new position in shares of Danaher Co. (NYSE:DHR) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,836 shares of the conglomerate’s stock, valued at approximately $459,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GUNN & Co INVESTMENT MANAGEMENT INC. purchased a new position in Danaher during the 4th quarter worth $306,000. Silver Oak Securities Incorporated purchased a new position in shares of Danaher during the 4th quarter worth about $203,000. Gilbert & Cook Inc. lifted its holdings in shares of Danaher by 4.9% during the 4th quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after acquiring an additional 86 shares during the period. Mather Group LLC. lifted its holdings in shares of Danaher by 6.6% during the 4th quarter. Mather Group LLC. now owns 3,386 shares of the conglomerate’s stock worth $783,000 after acquiring an additional 211 shares during the period. Finally, Choreo LLC lifted its holdings in shares of Danaher by 174.8% during the 4th quarter. Choreo LLC now owns 3,284 shares of the conglomerate’s stock worth $760,000 after acquiring an additional 2,089 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DHR shares. Leerink Partners increased their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Evercore ISI cut their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Barclays raised their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. The Goldman Sachs Group raised their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, Robert W. Baird raised their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by corporate insiders.

Danaher Stock Up 0.9 %

Shares of DHR stock traded up $2.29 during mid-day trading on Friday, reaching $269.31. 4,600,180 shares of the company were exchanged, compared to its average volume of 2,803,002. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company has a market capitalization of $199.47 billion, a P/E ratio of 45.65, a P/E/G ratio of 4.62 and a beta of 0.83. The business’s 50 day simple moving average is $260.05 and its 200 day simple moving average is $255.10.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the company earned $2.05 earnings per share. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. Research analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.